- Home
- ABSI vs CERS Comparison
ABSI vs CERS Comparison
Compare ABSI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- CERS
- Stock Information
- Founded
- ABSI 2011
- CERS 1991
- Country
- ABSI United States
- CERS United States
- Employees
- ABSI N/A
- CERS N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- ABSI Health Care
- CERS Technology
- Exchange
- ABSI Nasdaq
- CERS Nasdaq
- Market Cap
- ABSI 353.8M
- CERS 347.3M
- IPO Year
- ABSI 2021
- CERS 1997
- Fundamental
- Price
- ABSI $2.75
- CERS $1.29
- Analyst Decision
- ABSI Strong Buy
- CERS Strong Buy
- Analyst Count
- ABSI 5
- CERS 2
- Target Price
- ABSI $8.40
- CERS $3.50
- AVG Volume (30 Days)
- ABSI 2.5M
- CERS 991.7K
- Earning Date
- ABSI 05-13-2025
- CERS 05-01-2025
- Dividend Yield
- ABSI N/A
- CERS N/A
- EPS Growth
- ABSI N/A
- CERS N/A
- EPS
- ABSI N/A
- CERS N/A
- Revenue
- ABSI $4,534,000.00
- CERS $185,144,000.00
- Revenue This Year
- ABSI $158.58
- CERS $25.57
- Revenue Next Year
- ABSI $93.12
- CERS $10.54
- P/E Ratio
- ABSI N/A
- CERS N/A
- Revenue Growth
- ABSI N/A
- CERS 13.06
- 52 Week Low
- ABSI $2.01
- CERS $1.12
- 52 Week High
- ABSI $6.33
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- ABSI 42.92
- CERS 45.00
- Support Level
- ABSI $2.85
- CERS $1.22
- Resistance Level
- ABSI $2.94
- CERS $1.38
- Average True Range (ATR)
- ABSI 0.19
- CERS 0.07
- MACD
- ABSI -0.03
- CERS 0.00
- Stochastic Oscillator
- ABSI 14.13
- CERS 26.92
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.